Author(s):
Lili Fitriani, Nabila Andari Syafitri, Muhammad Nasrul Siregar, Adhitya Jessica, Erizal Zaini
Email(s):
erizal@phar.unand.ac.id
DOI:
10.52711/0974-360X.2025.00772 
Address:
Lili Fitriani, Nabila Andari Syafitri, Muhammad Nasrul Siregar, Adhitya Jessica, Erizal Zaini*
Department of Pharmaceutics, Faculty of Pharmacy, Universitas Andalas, 25163, Padang, Indonesia.
*Corresponding Author
Published In:
Volume - 18,
Issue - 11,
Year - 2025
ABSTRACT:
Etoricoxib is a non-steroidal anti-inflammatory drug (NSAID), included to class II of Biopharmaceutical Classification System (BCS) with low solubility in water and high permeability. This research aims to increase the solubility and dissolution of etoricoxib by preparing into co-amorphous phase using citric acid as the coformer at mol ratio of 1:1 by Liquid Assisted Grinding (LAG) method. Co-amorphous characterization were carried out by several solid state characterizations, which are Differential Scanning Calorimetry (DSC) analysis, Powder X-ray Diffraction (PXRD) analysis, Fourier Transform Infrared (FTIR) spectroscopy, and Scanning Electron Microscopy (SEM) analysis. To confirm the amount of co-amorph dissolved, the solubility test was carried out in distilled water for 24 hours using an orbital shaker and the dissolution test was done in phosphate-buffered medium for 45 minutes. Then, the quantity of etoricoxib was analysed by High Performance Liquid Chromatography (HPLC) using phosphate-buffered saline pH 3.5 and acetonitrile with a ratio of 55:45 as mobile phase. The characterization results showed a decrease in the melting point of co-amorphous in the DSC thermogram, and a decline in the intensity of the diffraction peaks in the PXRD diffractogram. FTIR spectrum showed no functional groups formed which confirmed by the wave-numbers of co-amourphous closed to those of the intact components. The morphology of co-amourphous depicted the irregular shape and pores which confirmed by SEM analysis. The solubility results in the co-amorphous showed an increase of 1.592 times and the dissolution efficiency results for 45 minutes showed an increase of 1.153 times compared to intact etoricoxib, respectively. In summary, the formation of co-amorphous etoricoxib - citric acid can enhance the solubility and dissolution of etoricoxib.
Cite this article:
Lili Fitriani, Nabila Andari Syafitri, Muhammad Nasrul Siregar, Adhitya Jessica, Erizal Zaini. Co-amorphous of Etoricoxib and Citric Acid with Enhancement in Solubility and Dissolution. Research Journal Pharmacy and Technology. 2025;18(11):5358-4. doi: 10.52711/0974-360X.2025.00772
Cite(Electronic):
Lili Fitriani, Nabila Andari Syafitri, Muhammad Nasrul Siregar, Adhitya Jessica, Erizal Zaini. Co-amorphous of Etoricoxib and Citric Acid with Enhancement in Solubility and Dissolution. Research Journal Pharmacy and Technology. 2025;18(11):5358-4. doi: 10.52711/0974-360X.2025.00772 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2025-18-11-34
REFERENCES:
1. Muthukumar S. Sankar C. Kumaran GA. Shalini S. Vinesha R. Varghese S. Formulation and Comparative Evaluation of Etoricoxib Loaded Osmotic Drug Delivery Systems. Research Journal of Pharmacy and Technology. 2019; 12(11): 5223. doi.org/10.5958/0974-360X.2019.00904.1
2. Elsegaie D. El-Nabarawi MA. Mahmoud HA. Teaima M. Louis D. A Comparative Study on Cyclodextrin Derivatives in Improving Oral Bioavailability of Etoricoxib as a Model Drug: Formulation and Evaluation of Solid Dispersion-Based Fast-Dissolving Tablets. Biomedicines. 2023; 11(9): 1–2. doi.org/10.3390/biomedicines11092440
3. Srinivasan S. Elhassan GO. Janakiraman AK. Kayarohanam S. Dey T. Moideen J. et al. Preparation and Characterization of Etoricoxib Ternary Complex for the Enhancement of Solubility. Journal of Pharmaceutical Negative Results. 2023; 14(02): 1703–4. doi.org/10.47750/pnr.2023.14.02.216
4. Sapkal SB. Adhao VS. Thenge RR. Darakhe RA. Shinde SA. Shrikhande VN. Formulation and characterization of solid dispersions of etoricoxib using natural polymers. Turkish Journal of Pharmaceutical Sciences. 2020; 17(1): 8–9. doi.org/10.4274/tjps.galenos.2018.04880
5. Bagade OM. Kad DR. Bhargude DN. Bhosale DR. Kahane SK. Consequences and impose of solubility enhancement of poorly water soluble drugs. Research Journal of Pharmacy and Technology. 2014; 7(5): 598–607.
6. Sharma D. Soni M. Kumar S. Gupta GD. Solubility enhancement–eminent role in poorly soluble drugs. Research Journal of Pharmacy and Technology. 2009; 2(2): 220–4.
7. Dani P. Puri V. Bansal AK. Solubility advantage from amorphous etoricoxib solid dispersions. Drug Development and Industrial Pharmacy. 2014; 40(1): 92–101.
8. Vinod Pote S. Bavaskar K. Jain A. Solubility Enhancement of Poorly Soluble Drug by using different Techniques. Research Journal of Pharmaceutical Dosage Forms and Technology. 2022; 14(4): 315–23. doi.org/10.52711/0975-4377.2022.00052
9. Tawar M. Raut K. Chaudhari R. Jain N. Novel Methods to Enhance Solubility of Water Insoluble Drugs. Asian Journal of Research in Pharmaceutical Sciences. 2022; 12(2): 151–6. doi.org/10.52711/2231-5659.2022.00026
10. Mishra N. Srivastava S. Characterization and solubility enhancement of etoricoxib in solid dispersion systems using lipid carriers Gelucire 44/14. Research Journal of Pharmacy and Technology. 2010; 3(2): 578–82.
11. Kulthe V V. Chaudhari PD. Characterization of Etoricoxib Solid Dispersions Prepared By Spray Drying Technique. Research Journal of Pharmacy and Technology. 2010; 3(4): 1158–66.
12. Vyas J. Parmar H. Patel H. Comparative Study of Etoricoxib Loaded Solid Dispersion and Beta-cyclodextrin Complexes for improvement of Dissolution Profile. Research Journal of Pharmaceutical Dosage Forms and Technology. 2020; 12(2): 63. doi.org/10.5958/0975-4377.2020.00011.7
13. Tran P. Pyo YC. Kim DH. Lee SE. Kim JK. Park JS. Overview of the manufacturing methods of solid dispersion technology for improving the solubility of poorly water-soluble drugs and application to anticancer drugs. Pharmaceutics. 2019; 11(3): 1–26. doi.org/10.3390/pharmaceutics11030132
14. Senthilkumar K. Vijaya C. Formulation Development of Mouth Dissolving Film of Etoricoxib for Pain Management. Advances in Pharmaceutics. 2015; 2015: 1–11. doi.org/10.1155/2015/702963
15. Chaudhary VB. Pharmacy SS. Cyclodextrin Inclusion Complex To Enhance Solubility of Poorly Water Soluble Drugs: a Review. Int J Pharm Sci Res. 2013; 4(1): 68–76.
16. Bhagwat A. Lokhande A. Pingat M. Doke R. Ghule S. Strategies and Mechanisms for Enhancing Drug Bioavailability through Co-Amorphous Mixtures-A Comprehensive Review. Research Journal of Pharmacy and Technology. 2025; 18(1): 409–14. doi.org/10.52711/0974-360X.2025.00063
17. Lodagekar A. Chavan RB. Mannava MKC. Yadav B. Chella N. Nangia AK. et al. Co amorphous valsartan nifedipine system: Preparation, characterization, in vitro and in vivo evaluation. European Journal of Pharmaceutical Sciences. 2019; 139: 1–27. doi.org/10.1016/j.ejps.2019.105048
18. Mizoguchi R. Waraya H. Hirakura Y. Application of Co-Amorphous Technology for Improving the Physicochemical Properties of Amorphous Formulations. Molecular Pharmaceutics. 2019; 16(5): 2142–52. doi.org/10.1021/acs.molpharmaceut.9b00105
19. Chavan RB. Thipparaboina R. Kumar D. Shastri NR. Co amorphous systems: A product development perspective. International Journal of Pharmaceutics. 2016; 515(1–2): 403–15.
20. PubChem. 2023.
21. Hirakawa Y. Ueda H. Takata Y. Minamihata K. Wakabayashi R. Kamiya N. et al. Co-amorphous formation of piroxicam-citric acid to generate supersaturation and improve skin permeation. European Journal of Pharmaceutical Sciences. 2021; 158: 1–22. doi.org/10.1016/j.ejps.2020.105667
22. Han J. Wei Y. Lu Y. Wang R. Zhang J. Gao Y. et al. Co-amorphous systems for the delivery of poorly water-soluble drugs: Recent advances and an update. Expert Opinion on Drug Delivery. 2020; 0(0). doi.org/10.1080/17425247.2020.1796631
23. Thayyil AR. Juturu T. Nayak S. Kamath S. Pharmaceutical Co-crystallization: Regulatory aspects, design, characterization, and applications. Advanced Pharmaceutical Bulletin. 2020; 10(2): 205–7. doi.org/10.34172/apb.2020.024
24. Karagianni A. Malamatari M. Kachrimanis K. Pharmaceutical cocrystals: New solid phase modification approaches for the formulation of APIs. Pharmaceutics. 2018; 10(1): 1–30. doi.org/10.3390/pharmaceutics10010018
25. Bhattacharyya I. Bhattacharyya SP. Sen S. Laha TK. Reverse phase high performance liquid chromatographic method for the analysis of etoricoxib in pharmaceutical dosage form. Asian Journal of Research in Chemistry. 2009; 2(3): 297–9.
26. D’Angelo A. Edgar B. Hurt AP. Antonijević MD. Physico-chemical characterisation of three-component co-amorphous systems generated by a melt-quench method. Journal of Thermal Analysis and Calorimetry. 2018; 134(1): 381–90. doi.org/10.1007/s10973-018-7291-y
27. Pekar KB. Lefton JB. McConville CA. Burleson J. Sethio D. Kraka E. et al. Mechanosynthesis of a Coamorphous Formulation of Creatine with Citric Acid and Humidity-Mediated Transformation into a Cocrystal. Crystal Growth and Design. 2021; 21(2): 1297–306. doi.org/10.1021/acs.cgd.0c01560
28. Zhao L. Hanrahan MP. Chakravarty P. Dipasquale AG. Sirois LE. Nagapudi K. et al. Characterization of Pharmaceutical Cocrystals and Salts by Dynamic Nuclear Polarization-Enhanced Solid-State NMR Spectroscopy. Crystal Growth and Design. 2018; 18(4): 4–6. doi.org/10.1021/acs.cgd.8b00203
29. Dutta A. Fourier Transform Infrared Spectroscopy. Vol. 2, Spectroscopic Methods for Nanomaterials Characterization. Elsevier Inc.; 2017. 73–93 p. doi.org/10.1016/B978-0-323-46140-5.00004-2
30. Jensen KT. Blaabjerg LI. Lenz E. Bohr A. Grohganz H. Kleinebudde P. et al. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts. Journal of Pharmacy and Pharmacology. 2016; 68(5): 615–24. doi.org/10.1111/jphp.12458
31. Jain S. Patel N. Lin S. Solubility and dissolution enhancement strategies: current understanding and recent trends. Drug Development and Industrial Pharmacy. 2015; 41(6): 875–87.
32. Bazzo GC. Pezzini BR. Stulzer HK. Eutectic mixtures as an approach to enhance solubility, dissolution rate and oral bioavailability of poorly water-soluble drugs. International Journal of Pharmaceutics. 2020; 588:119741.
33. Solares-Briones M. Coyote-Dotor G. Páez-Franco JC. Zermeño-Ortega MR. Contreras CM de la O. Canseco-González D. et al. Mechanochemistry: A green approach in the preparation of pharmaceutical cocrystals. Pharmaceutics. 2021; 13(6): 1–32. doi.org/10.3390/pharmaceutics13060790
34. Wang J. Chang R. Zhao Y. Zhang J. Zhang T. Fu Q. et al. Coamorphous loratadine-citric acid system with enhanced physical stability and bioavailability. Aaps Pharmscitech. 2017; 18: 2541–50.
35. Anderson NH. Bauer M. Boussac N. Khan-Malek R. Munden P. Sardaro M. An evaluation of fit factors and dissolution efficiency for the comparison of in vitro dissolution profiles. Journal of Pharmaceutical and Biomedical Analysis. 1998; 17(4–5): 811–22. doi.org/10.1016/S0731-7085(98)00011-9